Carlos S. Mamani-García
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carlos S. Mamani-García has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Abraham Edgar Gracia-Ramos
Department of Internal Medicine, General Hospital, National Medical Center La Raza, Instituto Mexicano del Seguro Social , Mexico City
1 shared publication - Brenda Caira-Chuquineyra
Facultad de Medicina, Universidad Nacional de San Agustín de Arequipa, Arequipa 04001, Peru
1 shared publication - Carlos Jesus Toro-Huamanchumo
Universidad San Ignacio de Loyola, Lima, Peru
1 shared publication - Cristian Díaz-Vélez
Universidad Privada Antenor Orrego, Trujillo, Perú. a. Gastroenterólogo, Investigador independiente. b. Maestría en investigación clínica
1 shared publication - Daniel Fernandez-Guzman
Carrera de Medicina Humana, Universidad Científica del Sur, Lima, Peru
1 shared publication - Diego Bustamante‐Paytan
Unidad de Investigación de Deterioro Cognitivo y Prevención de Demencia, Instituto Peruano de Neurociencias, Lima, Lima, Peru
1 shared publication
Latest Publications
- Open Access
- 20 October 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (20) , 13607
Factors Associated with Adequate Breastfeeding: Evidence from the Peruvian Demographic and Health Survey, 2019
Objective: To assess the factors associated with adequate breastfeeding (ABF) among Peruvian mothers during 2019. Materials and Methods: We performed a secondary analysis of the 2019 Demographic and Family Health Survey (ENDES) database of Peru. ABF was defined based on the recommendations of the World Health Organization, which defined it as starting breastfeeding within the first hour of life and continuing with exclusive breastfeeding for up to 6 months. To determine the factors associated with ABF, a Poisson generalized linear models with log-link function was used. Adjusted prevalence ratios (aPR) with their respective 95% confidence intervals (95% CI) were calculated. Results: A prevalence of ABF of 48.1% was identified among 11,157 women who reported at least one child in the last five years. Most of them were young (68.6%) and lived in urban areas (65.5%). Furthermore, being unemployed (aPR:1.02; 95% CI:1.00–1.04); residing on the coast, except for Metropolitan Lima (aPR:1.08; 95% CI:1.04–1.11), the highlands (aPR:1.14; 95% CI:1.11–1.18), and the jungle (aPR:1.20; 95% CI: 1.16–1.24); having had a vaginal delivery (aPR:1.30; 95% CI:1.27–1.05); and having two children (aPR:1.03; 95% CI:1.01–1.05) or three or more children (aPR:1.03; 95% CI:1.01–1.05) were associated with a higher frequency of ABF. Conclusions: One out of two women between 18–59 with children performed ABF. The factors associated with ABF were the current occupation, region of residence, type of delivery, and parity. Health policies and strategies should be implemented, considering our results, to promote maternal counseling by health personnel in order to increase the prevalence of ABF in the Peruvian population.
- 20 October 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (20) , 13607
Open AccessFactors Associated with Adequate Breastfeeding: Evidence from the Peruvian Demographic and Health Survey, 2019
Objective: To assess the factors associated with adequate breastfeeding (ABF) among Peruvian mothers during 2019. Materials and Methods: We performed a secondary analysis of the 2019 Demographic and Family Health Survey (ENDES) database of Peru. ABF was defined based on the recommendations of the World Health Organization, which defined it as starting breastfeeding within the first hour of life and continuing with exclusive breastfeeding for up to 6 months. To determine the factors associated with ABF, a Poisson generalized linear models with log-link function was used. Adjusted prevalence ratios (aPR) with their respective 95% confidence intervals (95% CI) were calculated. Results: A prevalence of ABF of 48.1% was identified among 11,157 women who reported at least one child in the last five years. Most of them were young (68.6%) and lived in urban areas (65.5%). Furthermore, being unemployed (aPR:1.02; 95% CI:1.00–1.04); residing on the coast, except for Metropolitan Lima (aPR:1.08; 95% CI:1.04–1.11), the highlands (aPR:1.14; 95% CI:1.11–1.18), and the jungle (aPR:1.20; 95% CI: 1.16–1.24); having had a vaginal delivery (aPR:1.30; 95% CI:1.27–1.05); and having two children (aPR:1.03; 95% CI:1.01–1.05) or three or more children (aPR:1.03; 95% CI:1.01–1.05) were associated with a higher frequency of ABF. Conclusions: One out of two women between 18–59 with children performed ABF. The factors associated with ABF were the current occupation, region of residence, type of delivery, and parity. Health policies and strategies should be implemented, considering our results, to promote maternal counseling by health personnel in order to increase the prevalence of ABF in the Peruvian population.
- Open Access
- 6 May 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (9) , 2615
Efficacy of Colchicine in the Treatment of COVID-19 Patients: A Systematic Review and Meta-Analysis
Objective: We assessed the efficacy of colchicine in COVID-19 patients through a systematic review. Methods: Six databases were searched until March 2022 for studies assessing colchicine versus control in hospitalized patients with COVID-19. The primary outcome was mortality, and secondary outcome was length of hospitalization. Inverse variance and random effect meta-analyses were performed. The strength of evidence was assessed using GRADE. Results: Nine studies (five randomized clinical trials (RCTs) and four non-randomized studies of intervention (NRSI); n = 13,478). Colchicine did not reduce mortality in comparison with the standard of care in RCTs (RR 0.99; 95%CI 0.90 to 1.10; p = 0.90); however, it did reduce mortality in NRSI studies (RR 0.45; 95%CI 0.26 to 0.77; p = 0.02). In the analysis of RCTs, colchicine did not reduce the length of hospitalization in comparison with the standard of care (MD: −2.25 days; 95%CI: −9.34 to 4.84; p = 0.15). Most studies were scored as having a high risk of bias. Quality of evidence was very low for primary and secondary outcomes. Conclusion: Colchicine did not reduce the mortality and length of hospitalization in comparison with the standard of care in hospitalized patients with COVID-19. The published evidence is insufficient and of very low quality to recommend treatment in patients with COVID-19.
- 6 May 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (9) , 2615
Open AccessEfficacy of Colchicine in the Treatment of COVID-19 Patients: A Systematic Review and Meta-Analysis
Objective: We assessed the efficacy of colchicine in COVID-19 patients through a systematic review. Methods: Six databases were searched until March 2022 for studies assessing colchicine versus control in hospitalized patients with COVID-19. The primary outcome was mortality, and secondary outcome was length of hospitalization. Inverse variance and random effect meta-analyses were performed. The strength of evidence was assessed using GRADE. Results: Nine studies (five randomized clinical trials (RCTs) and four non-randomized studies of intervention (NRSI); n = 13,478). Colchicine did not reduce mortality in comparison with the standard of care in RCTs (RR 0.99; 95%CI 0.90 to 1.10; p = 0.90); however, it did reduce mortality in NRSI studies (RR 0.45; 95%CI 0.26 to 0.77; p = 0.02). In the analysis of RCTs, colchicine did not reduce the length of hospitalization in comparison with the standard of care (MD: −2.25 days; 95%CI: −9.34 to 4.84; p = 0.15). Most studies were scored as having a high risk of bias. Quality of evidence was very low for primary and secondary outcomes. Conclusion: Colchicine did not reduce the mortality and length of hospitalization in comparison with the standard of care in hospitalized patients with COVID-19. The published evidence is insufficient and of very low quality to recommend treatment in patients with COVID-19.